Natera
NTRA
$193.03
-4.91%
Natera, Inc. is a diagnostic and research company operating in the healthcare sector, specifically within medical diagnostics and research. It leverages proprietary molecular and bioinformatics technology to develop and commercialize a suite of tests, including its flagship Panorama Non-Invasive Prenatal Test (NIPT), Horizon Carrier Screening (HCS), and the oncology-focused Signatera molecular residual disease (MRD) test. The company has established itself as a disruptive leader in cell-free DNA testing, particularly in reproductive health and oncology, with its Signatera test gaining significant traction for cancer monitoring. The current investor narrative is intensely focused on the company's path to sustained profitability, following a landmark Q4 2025 where it reported its first quarterly net income, and the continued explosive growth and market adoption of its Signatera oncology platform, which is seen as a major long-term growth driver.…
NTRA
Natera
$193.03
Related headlines
Investment Opinion: Should I buy NTRA Today?
Rating & Thesis: Hold. NTRA is a compelling but high-risk growth story at an inflection point; investors should wait for confirmation that Q4 profitability is sustainable before committing new capital, despite bullish analyst stances from firms like Morgan Stanley and Baird.
Supporting Evidence: The stock trades at a demanding 13.58x trailing sales, pricing in near-flawless execution. While Q4 revenue growth of 39.8% and a net margin of 7.1% are impressive, the TTM metrics (negative EPS, -9% net margin) show profitability is not annualized. The positive TTM free cash flow of $96.6 million and strong balance sheet (D/E: 0.125) are clear strengths, but the 17.6% 3-month price decline signals market skepticism about the durability of the recent positive trends.
Risks & Conditions: The two biggest risks are growth deceleration and failure to maintain quarterly profitability. This Hold rating would upgrade to a Buy if the company reports a second consecutive quarter of net income in Q1 2026 and the PS ratio compresses below 10x, offering a better risk/reward entry. It would downgrade to a Sell if revenue growth decelerates below 25% YoY or if the stock breaks decisively below its 52-week low support. At current levels, the stock is fairly valued relative to its transformed growth profile but remains overvalued on traditional profitability metrics, demanding perfect execution.
Sign up to view all
NTRA 12-Month Price Forecast
NTRA stands at a critical juncture. The fundamental story improved dramatically in Q4 2025 with its first net profit and robust cash flow, yet the stock's reaction has been negative, highlighting the market's focus on future sustainability rather than past achievement. The high valuation leaves no room for error, creating asymmetric risk where downside from missed expectations likely outweighs upside from meeting them in the near term. The stance is neutral, leaning cautiously optimistic on the long-term opportunity but recognizing the need for a more attractive entry point or concrete proof of sustained profitability. We would upgrade to bullish on evidence of a second profitable quarter and a lower valuation multiple; a return to losses would trigger a bearish view.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $250.94 and implied upside of +30.0% versus the current price.
Average Target
$250.94
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$154 - $251
Analyst target range
Analyst coverage for NTRA appears limited in the provided dataset, with only 5 analysts providing estimates for future revenue and EPS, but no explicit consensus price target, recommendation breakdown, or target range is available in the data. The lack of a clear consensus target and the minimal analyst count typically indicates the stock may be considered a mid-cap growth story with evolving coverage or that institutional research is still catching up to its fundamental transformation. The available institutional ratings show a pattern of reiterated bullish stances, with firms like Morgan Stanley (Overweight), Baird (Outperform), and Evercore ISI (Outperform) reaffirming their ratings in February and March 2026, suggesting sustained analyst confidence following the Q4 earnings report. The wide dispersion in historical valuation multiples and the stock's high beta of 1.68 underscore the elevated uncertainty and volatility inherent in the name, meaning price discovery is less guided by a dense analyst consensus and more driven by quarterly execution against high growth expectations.
Bulls vs Bears: NTRA Investment Factors
The investment debate for Natera centers on its recent, dramatic pivot to profitability against a backdrop of a richly valued, volatile growth stock. The bull case, currently supported by stronger evidence from the fundamental Q4 2025 results, rests on the company's proven 40% revenue growth, first net profit, and positive cash flow generation—a powerful trifecta for a disruptive diagnostics leader. The bear case hinges on the extreme valuation (13.6x PS) that leaves no margin for error, coupled with severe recent price weakness suggesting investor doubt. The single most important tension is whether the Q4 profitability inflection represents a sustainable new baseline or a one-time anomaly. The resolution of this question—through consistent delivery of positive earnings in the coming quarters—will definitively determine if the stock can grow into its premium valuation or face a painful de-rating.
Bullish
- First Quarterly Net Income: Q4 2025 marked a critical inflection point with the company reporting its first quarterly net income of $47.26 million and a net margin of 7.1%, a dramatic swing from a net loss of $87.54 million in Q3. This demonstrates a clear path to sustainable profitability, a key milestone for a high-growth company.
- Explosive Revenue Growth: Revenue growth accelerated to 39.79% YoY in Q4 2025, reaching $665.5 million, with sequential quarterly increases throughout the year. This robust growth, driven by the Signatera oncology platform, validates strong market adoption and execution against high expectations.
- The company generated positive free cash flow of $96.61 million on a TTM basis and $37.82 million in Q4 alone, alongside a robust current ratio of 3.39. This de-risks the investment by showing an improving ability to fund growth internally, reducing dependence on external capital.
- Healthy & Expanding Gross Margins: Gross margin expanded to 67.14% in Q4 2025 from 64.9% in Q3, indicating scalability and pricing power despite rapid revenue growth. This high-margin profile supports the potential for significant operating leverage as the company scales.
Bearish
- Extremely High Valuation Multiples: The stock trades at a trailing PS ratio of 13.58x and an EV/Sales of 12.10x, which are elevated multiples that price in near-perfect execution of future growth. Any deceleration in growth or profitability could trigger significant multiple compression, as seen historically.
- Profitability Not Yet Annualized: Despite the positive Q4, trailing twelve-month EPS remains negative at -$0.0066, and the forward P/E is deeply negative at -272.6x. The market is pricing in a rapid continuation of quarterly profits, leaving no room for execution stumbles in upcoming quarters.
- Severe Recent Price Weakness: The stock is down 17.62% over the past three months and 15.65% YTD, underperforming the S&P 500 by over 15 percentage points in both periods. This technical breakdown from its 2025 highs suggests fading momentum and investor skepticism about sustaining the recent breakout.
- High Beta & Volatility: With a beta of 1.68, NTRA is 68% more volatile than the broader market. This high volatility, evidenced by a 28.2% max drawdown, makes the stock unsuitable for risk-averse investors and amplifies downside moves during market corrections.
NTRA Technical Analysis
The prevailing price trend for NTRA has been a volatile consolidation within a downtrend from its 52-week highs, with the stock down 17.62% over the past three months and 15.65% year-to-date as of April 10, 2026. The current price of $193.03 sits approximately 24.7% below its 52-week high of $256.36 and 46.4% above its 52-week low of $131.81, positioning it in the lower-middle portion of its annual range, suggesting the momentum from its 2025 rally has faded and the stock is searching for a new equilibrium. Recent short-term momentum shows significant weakness, with a 1-month price decline of 1.82% and a 3-month decline of 17.62%, starkly contrasting with the still-positive 1-year return of 34.72%; this divergence signals a substantial correction or profit-taking phase following the prior strong uptrend, potentially exacerbated by broader market volatility given its high beta of 1.68. Key technical levels are clearly defined by the 52-week low of $131.81 as major support and the 52-week high of $256.36 as formidable resistance; a sustained break below the recent lows near $182 could signal a deeper correction towards the $131 support zone, while a recovery above the $230-$240 area would be needed to re-establish bullish momentum, with the stock's beta of 1.68 indicating it is 68% more volatile than the broader market, necessitating larger position sizing considerations for risk management.
Beta
1.68
1.68x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$132-$256
Price range past year
Annual Return
+34.7%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +2.6% |
| 3m | -17.6% | -2.3% |
| 6m | +14.0% | +2.6% |
| 1y | +34.7% | +27.3% |
| ytd | -15.6% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue trajectory exhibits robust growth, with Q4 2025 revenue reaching $665.5 million, representing a year-over-year growth rate of 39.79%. This acceleration is evident in the sequential quarterly revenue increases from $501.83 million in Q1 to $665.5 million in Q4, driven primarily by its core Product segment, which generated $661.16 million in the latest period. The company achieved a critical inflection point in Q4 2025, reporting its first quarterly net income of $47.26 million and a net margin of 7.1%, a dramatic swing from a net loss of $87.54 million in Q3. Gross margin remains healthy at 67.14% for Q4, showing stability and slight expansion from 64.9% in Q3, indicating scalability and pricing power despite the rapid revenue growth. The balance sheet and cash flow position are strengthening, with a very low debt-to-equity ratio of 0.125 and a robust current ratio of 3.39, reflecting ample liquidity. Most notably, the company generated positive free cash flow of $96.61 million on a trailing twelve-month basis and $37.82 million in Q4 alone, demonstrating an improving ability to fund its operations and growth internally, which significantly de-risks the investment thesis as it moves towards sustainable profitability.
Quarterly Revenue
$665500000.0B
2025-12
Revenue YoY Growth
+0.39%
YoY Comparison
Gross Margin
+0.67%
Latest Quarter
Free Cash Flow
$96613000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given Natera's recent quarterly net income was positive but its trailing twelve-month EPS remains negative at -$0.0066, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric, as profitability is not yet consistent on an annual basis. The stock trades at a trailing PS ratio of 13.58x and an EV/Sales of 12.10x, which are elevated multiples that price in significant future growth. Comparing to industry averages is challenging due to missing peer data, but the high PS ratio suggests the market is valuing Natera's revenue growth premium, particularly for its oncology segment. Historically, Natera's valuation has compressed significantly from pandemic-era highs; its current PS ratio of 13.58x is well below its historical peaks above 70x seen in mid-2021 and represents a substantial de-rating as the company has grown into its valuation. However, it remains above levels seen in late 2022 and early 2023, indicating the market is still assigning a premium for its transformed growth profile and path to profitability, leaving the stock sensitive to any execution missteps or growth deceleration.
PE
-150.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -124x~166x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-115.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, given the stock's elevated 13.58x PS ratio and negative trailing P/E. While Q4 showed a net profit, annual profitability is not yet achieved (TTM EPS: -$0.0066), and the company remains dependent on continued 40%+ revenue growth to justify its multiples. Any deceleration in the Signatera oncology segment's growth, which is a key driver, could severely impact sentiment. Furthermore, while cash flow is now positive, the high P/CF ratio of 145.5x indicates the market is pricing in exponential future cash flow growth, creating high execution risk.
Market & Competitive Risks: NTRA faces significant market risk due to its high beta of 1.68, making it highly sensitive to broader market downturns and rotations away from growth stocks. Competitive risks are inherent in the fast-evolving molecular diagnostics space, where technological disruption and payer reimbursement changes are constant threats. The stock's valuation, though below historical peaks above 70x PS, remains at a premium that is vulnerable to compression if sector-wide growth stock multiples contract, especially in a higher interest rate environment.
Worst-Case Scenario: The worst-case scenario involves a 'growth scare' where Q1 2026 results show a reversion to net losses and a material slowdown in revenue growth below 30% YoY. This would shatter the nascent profitability narrative, trigger analyst downgrades, and catalyze a rapid de-rating of the PS multiple towards its 52-week low valuation implied by the price of $131.81. Given the stock's high volatility, such a scenario could see a swift decline of approximately -32% from the current $193.03 to retest the 52-week low, with potential for an overshoot given the lack of strong technical support below that level.
FAQ
The key risks are: 1) Valuation & Execution Risk: The high PS ratio of 13.58x leaves the stock vulnerable to severe multiple compression if growth decelerates or profitability falters. 2) Financial Model Risk: Despite a positive Q4, annual profitability is not yet secured (TTM EPS: -$0.0066). 3) Market Risk: Its high beta of 1.68 means it will fall significantly more than the market during downturns. 4) Competitive/Regulatory Risk: The molecular diagnostics space is rapidly evolving, with constant threats from new technologies and payer reimbursement changes. The valuation risk is currently the most severe due to the stock's recent price weakness.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $190 and $225 as it digests its valuation amid volatile quarterly results. The Bull Case (30% probability) targets $240 to $256, requiring sustained profitability and accelerating growth to re-rate the multiple. The Bear Case (20% probability) sees a drop to $132-$175 if growth stumbles and losses return. The most likely outcome is the Base Case, predicated on the assumption that revenue growth remains strong (~35%) but profitability proves inconsistent, keeping the stock in a consolidation phase.
NTRA is fairly valued relative to its recent fundamental transformation but overvalued on traditional metrics. The trailing PS ratio of 13.58x is high, reflecting a premium for its 40% revenue growth and path to profitability, as traditional value metrics like P/E are negative. Compared to its own history, the multiple is well below pandemic-era peaks above 70x but above levels seen in late 2022. The valuation implies the market expects the company to maintain hyper-growth while rapidly expanding net margins into the double-digits. Any stumble would likely cause the stock to be deemed overvalued quickly.
NTRA is a high-risk, high-reward stock that may be a good buy for aggressive growth investors, but not for most. The recent Q4 profitability inflection is promising, but the stock's elevated 13.6x price-to-sales ratio prices in flawless execution. With 30% upside to its 52-week high but 32% downside to its 52-week low, the risk/reward is balanced at current levels. It could be a good buy on a significant pullback towards $160-$170 or after a confirmation of sustained profitability in the next quarterly report. Conservative investors should avoid it due to its high beta of 1.68 and earnings volatility.
NTRA is suitable only for long-term investors with a minimum 3-5 year horizon who can withstand extreme volatility. The company is in a capital-intensive growth phase, pays no dividend, and its earnings are highly volatile, making it a poor candidate for short-term trading or income. Its high beta of 1.68 and dependence on multi-year clinical adoption cycles for Signatera mean the investment thesis will take years to fully play out. Short-term traders would be exposed to whipsaw action around earnings, while long-term holders are betting on the company dominating the MRD testing market.